Increased Usage of Health Economics and Outcome Research (HEOR) by Pharma Cos in Decision-making Process


Published Date : Apr 18, 2017

ALBANY, New York, April 18, 2017 : MarketResearchReports.biz has announced the addition of a new report, titled “Evolving Market Access Strategies - Pricing and Reimbursement Landscape in Major Developed Pharmaceutical Markets” to its offering. The in-depth study focusses on major market access strategies such as Health Economics and Outcome Research (HEOR) and evaluates the scope of Health Technology Assessment (HTA). The report offers detailed insights into pricing and reimbursements strategies of various pharmaceutical manufacturers.

The study analyzes key HTA regulatory policies in major nations and carefully evaluates pharmacoeconomics modelling methods in HEOR. The study assesses the multiple dimensions of the HEOR process using a number of clinical studies. The research assesses the pricing pressures faced by several pharmaceutical companies in developing and developed regions. In addition, the study evaluates the impact of HEOR implementation on the competitive dynamics. The model is increasingly used by pharmaceutical players and medical device manufacturers to communicate the value of their innovation to payers, physicians, and patients.

The report focusses on the need for integrating various market access strategies into the initial stages of drug development. Furthermore, the increasing benefit of HTA in guiding informed strategy formulation in case of limited evidence is boosting its adoption. The reports elaborates on the prominent pricing and reimbursement policies in major regions such as North America, Europe, and Asia Pacific with a focus on the U.K., Germany, Italy, France, Spain, and Japan. The use of HEOR in understanding the level of competition in the pharmaceutical industry is adequately covered in the study.

For Sample Copy, click here: http://www.marketresearchreports.biz/sample/sample/561075

Health economics and outcomes research (HEOR) is increasingly used by several pharmaceutical players to guide healthcare decision-making in various emerging and established markets, such as the U.S., the U.K., and Japan. A large number of healthcare payers are using HEOR data to gain a competitive edge over others. In addition, the use of systemic value development plan (SVDP) has enhanced the potential of HEOR. In a number of developed nations, HTA has soared in popularity due to its increased adoption in various drug development activities. The role of HTA in bridging the gap between regulatory and reimbursement submissions has led numerous players to implement HTA. This has helped the companies to better understand the market prospects of their major products. However, the heterogeneity in HTA practices may increase the complexity of the market access environment.

Nevertheless, in the coming years, HTA practices will gain more relevance in clinical development, since a significant part of post-marketing risks is strongly influenced by the coverage provided by third-party payers, including managed service providers. The report takes a closer look at the recent clinical trials and enumerates the challenges for achieving optimum market access.

To order report Call Toll Free: 866-997-4948 or send an email on sales@marketresearchreports.biz